Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports
Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,
Novo Shares Fall on Safety Data for New Weight-Loss Drug
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.
Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates.
Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for further reductions in longer trials.
Novo Nordisk faces US congressional grilling over price of weight loss drugs
Novo Nordisk’s chief executive is preparing for a showdown next week with progressive firebrand Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of US government price controls.
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some psychiatric side effects, new data show.
The Price War in Weight-Loss Drugs Is Here
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...
NBC New York12d
Novo Nordisk weight-loss drug is effective for kids as young as 6, study shows
Based on the results of the trial, drugmaker Novo Nordisk has asked ... children who received the drug slowed weight ...
The next big market for weight-loss drugs: children
Novo Nordisk's weight loss drug, Saxenda, helped children ages six to 11 reduce their body mass index in a recent trial.
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
BioSpace2d
Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but Neuropsychiatric Events Reported
Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...